Urinary Tract Infection disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

UTI MCID: URN019 MIFTS: 52	Urinary Tract Infection (UTI) Categories: Infectious diseases, Nephrological diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Urinary Tract Infection

MalaCards integrated aliases for Urinary Tract Infection:

Name: Urinary Tract Infection ¹¹ ⁵ ¹⁴ ¹⁶ ⁷⁵

Urinary Tract Infections ⁴¹ ⁴³ ¹⁴

Uti Nos - [urinary Tract Infection Nos] ³³

Uti - [urinary Tract Infection] ³³

E Coli Urinary Tract Infection ³³

Urinary Tract Infection Nos ³³

Escherichia Coli Uti ³³

Urosepsis Nos ³³

E Coli Uti ³³

Uti ¹¹

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Nephrological diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Diseases of the genitourinary system

Other diseases of urinary system

Other disorders of urinary system

Urinary tract infection, site not specified

ICD11: ³³

Diseases of the genitourinary system

Diseases of the urinary system

Certain specified diseases of urinary system

Urinary tract infection, site not specified

Urinary tract infection, site not specified due to other agent

Urinary tract infection, site not specified, due to Escherichia coli

Urinary tract infection, site not specified, due to Klebsiella pneumoniae

Urinary tract infection, site not specified, due to Proteus

External Ids:

Disease Ontology ¹¹ DOID:0080784

MeSH ⁴³ D014552

ICD10 ³¹ N39.0

EFO ¹⁶ EFO_0003103

ICD11 ³³ 109033803 1848472780 1848472780/other more

Sources

Summaries for Urinary Tract Infection

MedlinePlus: ⁴¹ The urinary system is the body's drainage system for removing wastes and extra water. It includes two kidneys, two ureters, a bladder, and a urethra. Urinary tract infections (UTIs) are the second most common type of infection in the body. You may have a UTI if you notice: Pain or burning when you urinate Fever, tiredness, or shakiness An urge to urinate often Pressure in your lower belly Urine that smells bad or looks cloudy or reddish Pain in your back or side below the ribs People of any age or sex can get UTIs. But about four times as many women get UTIs as men. You're also at higher risk if you have diabetes, need a tube to drain your bladder, or have a spinal cord injury. If you think you have a UTI it is important to see your doctor. Your doctor can tell if you have a UTI with a urine test. Treatment is with antibiotics. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary: Urinary Tract Infection, also known as urinary tract infections, is related to acute cystitis and cystitis. An important gene associated with Urinary Tract Infection is EBF3 (EBF Transcription Factor 3), and among its related pathways/superpathways are Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers and Spinal cord injury. The drugs Piperacillin and Ceftriaxone have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, kidney and prostate, and related phenotype is cardiovascular system.

Disease Ontology: ¹¹ An urinary system disease that is characterized by an infection in any part of the urinary system, including the kidneys, ureters, bladder or urethra.

Wikipedia: ⁷⁵ A urinary tract infection (UTI) is an infection that affects part of the urinary tract. When it affects... more...

Sources

Related Diseases for Urinary Tract Infection

Diseases in the Urinary Tract Infection family:

Urinary Tract Infections, Recurrent

Diseases related to Urinary Tract Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1344)

#	Related Disease	Score	Top Affiliating Genes
1	acute cystitis	33.1	UPK1A UMOD LCN2 IL6 CXCL8
2	cystitis	32.9	UPK1A UMOD TNF IL6 CXCL8 CRP
3	bacteriuria	32.9	UMOD IL6 CXCL8 CRP ALB
4	pyuria	32.7	LCN2 KLK3 IL6 CRP ALB
5	pyelonephritis	32.3	UMOD TNF LCN2 IL6 CXCL8 CRP
6	urethral syndrome	32.3	TNF KLK3 IL6 CXCL8 CRP
7	vesicoureteral reflux	32.3	UPK1A UMOD LCN2 EBF3 CXCL8 CRP
8	ureteral disease	32.2	UMOD TNF LCN2 IL6 CCR6 ALB
9	acute pyelonephritis	31.9	VIM UBAC1 TNF LCN2 IL6 CXCL8
10	neurogenic bladder	31.9	UPK1A KLK3 INS EBF3 CRP ALB
11	hydronephrosis	31.8	LCN2 KLK3 IL6 CXCL8 CRP ALB
12	urolithiasis	31.8	UMOD IL6 HOGA1 ALB
13	chronic pyelonephritis	31.7	UMOD CRP ALB
14	klebsiella pneumonia	31.6	CRP ALB
15	toxic shock syndrome	31.6	TNF IL6 CXCL8 CRP
16	urinary tract obstruction	31.6	UMOD TNF LCN2 KLK3 IL6 CRP
17	prostatitis	31.5	TNF KLK3 IL6 CXCL8
18	diarrhea	31.5	TNF IL6 CXCL8 ALB
19	pneumonia	31.4	TNF IL6 CXCL8 CRP ALB
20	urinary system disease	31.4	UMOD KLK3 CCR6 ALB
21	chronic kidney disease	31.4	UMOD TNF LCN2 INS IL6 CRP
22	bowel dysfunction	31.3	TNF LCN2 INS IL6 CRP ALB
23	endocarditis	31.3	TNF LCN2 IL6 CXCL8 CRP ALB
24	vaginitis	31.3	TNF IL6 CXCL8 CCR6
25	interstitial cystitis	31.3	UPK1A TNF IL6
26	haemophilus influenzae	31.3	TNF CXCL8
27	liver cirrhosis	31.3	TNF INS IL6 ALB
28	kidney disease	31.3	UMOD TNF LCN2 INS IL6 CXCL8
29	chlamydia	31.3	TNF IL6 CXCL8 CRP
30	meningitis	31.3	TNF IL6 CXCL8 CRP ALB
31	osteomyelitis	31.3	TNF IL6 CXCL8 CRP
32	nutritional deficiency disease	31.3	IL6 CRP CCR6 ALB
33	sickle cell anemia	31.3	TNF IL6 CRP ALB
34	bilirubin metabolic disorder	31.2	TNF INS IL6 CXCL8 CRP ALB
35	vaginal discharge	31.2	TNF IL6 CXCL8 CRP ALB
36	urethritis	31.2	TNF KLK3 IL6 CXCL8 CRP CD248
37	bacterial meningitis	31.2	TNF CXCL8 CRP
38	prostatic hypertrophy	31.2	KLK3 INS CRP ALB
39	cerebrovascular disease	31.2	TNF INS IL6 CRP CCR6 ALB
40	gastroenteritis	31.2	TNF IL6 CXCL8 CRP ALB
41	pre-eclampsia	31.2	TNF INS IL6 CXCL8 CRP ALB
42	ureterolithiasis	31.1	KLK3 CRP ALB
43	deficiency anemia	31.1	TNF INS IL6 CRP CCR6 ALB
44	congestive heart failure	31.1	TNF INS IL6 ALB
45	autoimmune disease	31.1	TNF INS IL6 CRP CCR6
46	adult syndrome	31.1	TNF INS IL6 CRP
47	bacterial vaginosis	31.1	TNF IL6 CXCL8 CCR6
48	acute kidney failure	31.1	UMOD LCN2 IL6 ALB
49	peritonitis	31.1	TNF LCN2 IL6 CXCL8 CRP ALB
50	polycystic kidney disease	31.1	UMOD TNF LCN2 INS CRP ALB

Graphical network of the top 20 diseases related to Urinary Tract Infection:

Sources

Symptoms & Phenotypes for Urinary Tract Infection

MGI Mouse Phenotypes related to Urinary Tract Infection:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cardiovascular system	MP:0005385	9.4	ALB CCR6 CRP IL6 INS KLK3

Sources

Drugs & Therapeutics for Urinary Tract Infection

Drugs for Urinary Tract Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 361)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Piperacillin

Approved

Phase 4

66258-76-2

43672

Ceftriaxone

Approved

Phase 4

73384-59-5

5479530

Cefixime

Approved, Investigational

Phase 4

79350-37-1

5362065

Ciprofloxacin

Approved, Investigational

Phase 4

85721-33-1, 93107-08-5

2764

Acetylcholine

Approved, Investigational

Phase 4

51-84-3

187

Sulbactam

Approved

Phase 4

68373-14-8

5316

Doripenem

Approved, Investigational

Phase 4

148016-81-3

73303

Ibuprofen

Approved

Phase 4

15687-27-1

3672

Zinc cation

Approved, Experimental, Investigational

Phase 4

7440-66-6, 23713-49-7

32051

Bacitracin

Approved, Vet_approved

Phase 4

1405-87-4

10909430

Framycetin

Approved, Experimental, Vet_approved

Phase 4

1404-04-2, 119-04-0, 3947-65-7

413349 8378

Vancomycin

Approved

Phase 4

1404-90-6

14969

Belladonna

Approved, Experimental

Phase 4

Methylene blue

Approved, Investigational

Phase 4

61-73-4

6099

Apricot

Approved

Phase 4

Cefadroxil

Approved, Vet_approved, Withdrawn

Phase 4

66592-87-8, 50370-12-2

47965

Lactitol

Approved, Investigational

Phase 4

585-86-4

157355

Halofantrine

Approved

Phase 4

69756-53-2

37393

Ampicillin

Approved, Vet_approved

Phase 4

69-53-4

6249

Amoxicillin

Approved, Vet_approved

Phase 4

26787-78-0

33613

Methyltestosterone

Approved

Phase 4

58-18-4

6010

Testosterone undecanoate

Approved, Investigational

Phase 4

5949-44-0

21873174 65157

Testosterone enanthate

Approved

Phase 4

315-37-7

9416

Testosterone

Approved, Investigational

Phase 4

58-22-0

5408 6013

Clindamycin

Approved, Vet_approved

Phase 4

18323-44-9, 24729-96-2

29029

Avibactam

Approved

Phase 4

1192500-31-4

Colistin

Approved

Phase 4

1264-72-8, 1066-17-7

5311054

Tigecycline

Approved

Phase 4

220620-09-7

5282044

Benzylpenicillin

Approved, Vet_approved

Phase 4

61-33-6

5904

Procaine

Approved, Investigational, Vet_approved

Phase 4

59-46-1

4914

Metronidazole

Approved

Phase 4

443-48-1, 69198-10-3

4173

Sugarcane

Approved

Phase 4

Linezolid

Approved, Investigational

Phase 4

165800-03-3

441401

Tetracycline

Approved, Vet_approved, Withdrawn

Phase 4

60-54-8

5353990

Amikacin

Approved, Investigational, Vet_approved

Phase 4

37517-28-5, 39831-55-5

37768

Cephalexin

Approved, Investigational, Vet_approved

Phase 4

15686-71-2

27447

Tobramycin

Approved, Investigational

Phase 4

32986-56-4

36294

Fosfomycin

Approved

Phase 4

23155-02-4

446987

Imipenem

Approved

Phase 4

74431-23-5, 64221-86-9

104838

Cilastatin

Approved, Investigational

Phase 4

82009-34-5

6435415

Levofloxacin

Approved, Investigational

Phase 4

100986-85-4

149096

Ofloxacin

Approved

Phase 4

82419-36-1

4583

Iodine

Approved, Investigational

Phase 4

7553-56-2

807

Povidone-iodine

Approved

Phase 4

25655-41-8

Povidone K30

Approved, Experimental, Withdrawn

Phase 4

9003-39-8

6917 131751496

Cefoxitin

Approved

Phase 4

35607-66-0

441199

Cefotaxime

Approved

Phase 4

63527-52-6

5742673 456256

Cathine

Approved, Experimental, Illicit, Vet_approved, Withdrawn

Phase 4

14838-15-4, 492-39-7

131954576 4786 26934

Guaifenesin

Approved, Investigational, Vet_approved

Phase 4

93-14-1

3516

Norfloxacin

Approved

Phase 4

70458-96-7

4539

Interventional clinical trials:

(show top 50) (show all 607)

#	Name	Status	NCT ID	Phase	Drugs
1	Randomised Clinical Trial Comparing Fosfomycin vs. Nitrofurantoin for Treatment of Uncomplicated Lower Urinary Tract Infection in Female Adults at Increased Risk of Antibiotic-resistant Bacterial Infection	Unknown status	NCT01966653	Phase 4	nitrofurantoin;fosfomycin
2	Efficacy of Temocillin in Urinary Tract Infection Due to ESBL Producing and AmpC Hyperproducing Enterobacteriaceae	Unknown status	NCT02681263	Phase 4	Temocillin
3	A Open Multi-center Clinical Study on Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection	Unknown status	NCT01897831	Phase 4	xin te mie
4	The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Symptomatic Non-complicated Urinary Tract Infection in Females	Unknown status	NCT02094703	Phase 4	Levofloxacin;Solifenacin succinate;Placebo (for Solifenacin succinate)
5	Randomized Placebo-Controlled Trial of Gentamicin Bladder Instillation for the Prevention of Urinary Tract Infection in Adults at High Risk for Cystitis Due to Intermittent Catheterization	Unknown status	NCT01884467	Phase 4	Gentamicin;Placebo
6	Safety and Efficacy of Fixed-low-dose Amikacin for Urinary Tract Infection on the Elderly Patient	Unknown status	NCT04197739	Phase 4	Amikacin
7	Sanjin Tablets for the Treatment of Acute Simple Lower Urinary Tract Infection and Its Influence on Recurrence Rate: a Randomized, Double Blind, Parallel Control of Positive Drugs, Multi-center Clinical Study	Unknown status	NCT03658291	Phase 4	Sanjin tablets;Sanjin tablets simulants;Levofloxacin
8	Low Dose Estriol With Lactobacilli (Gynoflor) Treatment for Preventing Recurrent Urinary Tract Infection in Postmenopausal Women: A Randomized, Open, Parallel-Group Study	Unknown status	NCT00900653	Phase 4	Gynoflor E (low dose estriol with lactobacillus)
9	The Impact of Antimicrobial Treatment for Asymptomatic Bacteriuria in Renal Transplant Patients	Unknown status	NCT02113774	Phase 4
10	Comparison of the Effect of Applying Povidone-iodine and Chlorhexidine Solutions for Perinea Washing on Bacteriuria Rate and Type in Patients With Urinary Catheter in Intensive Care Unit	Unknown status	NCT02032394	Phase 4	Povidone-iodine;Chlorhexidine;Normal saline
11	An Open Label Non Placebo Study to Evaluate Efficacy and Safety of Levofloxacin as an Empirical Therapy in Patients With Complicated Urinary Tract Infections	Unknown status	NCT03160807	Phase 4	Levofloxacin
12	A Randomised, Double-blind, Placebo Controlled Trial Evaluating the Effectiveness of a Cranberry Concentrate (CranrichTM) in Preventing Recurrent Urinary Tract Infections in Adult Women	Unknown status	NCT02454309	Phase 4
13	Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic Urinary Tract Infections Due to Extended-spectrum β-lactamase (ESBL)-Producing Escherichia Coli or Klebsiella Pneumoniae - (CAPITIS Study)	Unknown status	NCT03891433	Phase 4	Meropenem;Ertapenem 1000 MG;Piperacillin, Tazobactam 4-0.5G Solution for Injection
14	Evaluation of the Effectiveness of Antibiotic Prophylaxis in Children With a History of Upper Urinary Tract Infections:a Multicentre Randomised Study	Unknown status	NCT00156546	Phase 4	antibiotic to reduce the recurrence of infection
15	Noroxin Efficacy and Safety Trial	Unknown status	NCT03506256	Phase 4	Norfloxacin 400 MG
16	Recurrent Urinary Tract Infections in Children: Bacterial Identification, Antibiotic Susceptibility Profiling and Cytokine Levels Associated With Antibiotic Prophylaxis	Completed	NCT02357758	Phase 4	Antibiotic Prophylaxis
17	Nitrofurantoin Administration for the Prevention of Short-Term Catheter Associated Urinary Tract Infection After Pelvic Surgery (NAUTICA): A Randomized Controlled Trial	Completed	NCT03287089	Phase 4	Nitrofurantoin 100 MG;Placebo Oral Tablet
18	Relevance of Biomarkers and Clinical Predictors of Outcome in Unselected Population With Febrile Urinary Tract Infection at Primary Care and Emergency Department in a Prospective, Randomized Cohort Trial Comparing Short (7 Days) Antibiotic Treatment With Conventional Treatment (14 Days)	Completed	NCT00809913	Phase 4	short treatment (ciprofloxacin)
19	The Bacteriuria in Renal Transplantation (BiRT) Study: A Prospective, Randomized, Parallel-group, Multicenter, Open-label, Superiority Trial Comparing Antibiotics Versus no Treatment in the Prevention of Symptomatic Urinary Tract Infection in Kidney Transplant Recipients With Asymptomatic Bacteriuria	Completed	NCT01871753	Phase 4
20	Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women: A Randomized Clinical Trial	Completed	NCT01958073	Phase 4	Conjugated Estrogen Vaginal Cream;Estradiol Ring;Placebo
21	Introduction of Nitrofurantoin in Place of Ciprofloxacin in Patients of Uncomplicated Urinary Tract Infection: a Controlled Clinical Trial to Establish the Relationship Between Revival and Associated Shift in Sensitivity Pattern of the Causative Microbes	Completed	NCT03716804	Phase 4	Tablet Nitrofurantoin;Tablet Ciprofloxacin/ Tablet Cefixime/ Tablet Cefuroxime
22	Does Prophylaxis With Macrobid Reduce the Incidence of Urinary Tract Infection in Patients Who Receive a Sub-Urethral Sling for the Treatment of Stress Urinary Incontinence: Randomized, Double Blinded Placebo Controlled Clinical Trial	Completed	NCT00734968	Phase 4	Nitrofurantoin
23	Clinical and Microbiologic Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection in Adult Women.	Completed	NCT03366207	Phase 4	Ciprofloxacin
24	Perioperative Disodium Fosfomycin in the Prophylaxis of Urinary Tract Infection in Kidney Transplant Recipients. Controlled Clinical Trial (PERIFOS Trial)	Completed	NCT03235947	Phase 4	Fosfomycin disodium;Trimethoprim / Sulfamethoxazole;Intravenous placebo
25	Reducing Antibiotic Use for Uncomplicated Urinary Tract Infection in General Practice by Treatment With Uva Ursi (UU)- a Comparative Effectiveness Trial	Completed	NCT03151603	Phase 4	Arctuvan;Fosfomycin;Placebo to Arctuvan;Placebo to Fosfomycin
26	Open Label Study on the Bacteriological and Clinical Efficacy and Safety of a Nitrofurantoin Formulation Given Twice Daily (Bid) for Seven Days in Uncomplicated Urinary Tract Infection in Adults	Completed	NCT01092351	Phase 4	Nitrofurantoin
27	A Randomized, Multicenter, Parallel Group Study to Evaluate Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder	Completed	NCT01388413	Phase 4	Weekly Oral Cyclic Antibiotic programme
28	Immediate vs. Conditional Use of Antibiotics in Uncomplicated Urinary Tract Infection (UTI) - a Comparative Effectiveness Study in General Practice (ICUTI)	Completed	NCT01488955	Phase 4	Ibuprofen;Fosfomycin-Trometamol
29	Antibiotic Prophylaxis for Urinary Tract Infection in Patients Requiring Catheterization After Urogynecologic Surgery	Completed	NCT01450800	Phase 4	Nitrofurantoin;Placebo
30	Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection: a Non-Inferiority Trial	Completed	NCT03508921	Phase 4	Extended Antibiotics
31	Fosfomycin-Trometamol in Urinary Tract Infection Prophylaxis After Kidney Transplantation. Randomized Controlled Trial.	Completed	NCT01820897	Phase 4	Fosfomycin-Trometamol;Sulfamethoxazole trimethoprim
32	Prospective, Open Label Non-comparative, Multi-center Trial to Evaluate the Efficacy and Safety of Cipro® XR 500 mg Once Daily for 3 Days in Treating Female Patients With Acute, Uncomplicated, Symptomatic Lower Urinary Tract Infections	Completed	NCT00669994	Phase 4	Ciprofloxacin
33	Cipro® XR Excellence in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections	Completed	NCT00676533	Phase 4	Cipro XR (Ciprofloxacin, BAYQ3939)
34	Pharmacokinetics of Ciprofloxacin in Pediatric Patients With Emphasis on Renal Excretion	Completed	NCT02598362	Phase 4	ciprofloxacin
35	Use of Standardized Delegation Form in Diagnosing and Treating Acute Cystitis in Primary Care Facilities.	Completed	NCT01132131	Phase 4
36	Use of Antibiotic Prophylaxis on Urethral Catheter Withdrawal: A Randomized Double-Blind Placebo-Controlled Trial	Completed	NCT00126698	Phase 4	trimethoprim-sulfamethoxazole;ciprofloxacin
37	Randomized Controled Multicentric Trial, of Non Inferiority, Comparing Two Durations of Antibiotherapy (5 Days Versus 10 Days) in COMMUNAUTARY Acute Uncomplicated Pyelonephritis.	Completed	NCT00873626	Phase 4	levofloxacin, ciprofloxacin and ofloxacin (fluoroquinolones)
38	A Randomized, Controlled, Multicentre Trial of Collateral Damage on the Intestinal Microbiota Inferred by Temocillin Versus Cefotaxime in Patients Receiving Empirical Treatment for Febrile Urinary Tract Infections	Completed	NCT02959957	Phase 4	Temocillin;Cefotaxime
39	Antibiotic Prophylaxis After Acute Pyelonephritis for Prevention of Urinary Tract Infections in Children With Vesico-Ureteral Reflux.	Completed	NCT00382343	Phase 4	Sulfamethoxazole/trimethoprim
40	Prospective, Open-Label, Noncomparative, Multicenter Study to Evaluate the Efficacy and Safety of Ciprofloxacin Extended Release (Cipro XR) 1000 mg Tablets Given Once Daily for 7 to 14 Days in the Treatment of Patients 18 Years or Older With Complicated Urinary Tract Infections Caused by Pseudomonas Aeruginosa and Other Common Uropathogens	Completed	NCT00481689	Phase 4	Cipro XR (Ciprofloxacin, BAYQ3939)
41	A Post Marketing Surveillance Study on the Safety and Effectiveness of Doripenem in the Therapy of Thai Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections	Completed	NCT00965848	Phase 4	Doripenem
42	Evaluation of Suprapubic Noble Metal Alloy BIP Foley Catheter in the Prevention of Catheter-associated Urinary Tract Infections in Spinal Cord Injured Patients	Completed	NCT02808000	Phase 4
43	Antibiotic Treatment for Intermittent Bladder Catheterisation: A Randomised Controlled Trial of Once Daily Prophylaxis	Completed	NCT02145338	Phase 4	Nitrofurantoin or Trimethoprim or Cefalexin
44	EXPRESS: Evaluating Cipro XR Patient Response, Education, Safety, and Satisfaction	Completed	NCT00663806	Phase 4
45	Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Infection: A Randomized Controlled Study	Completed	NCT03099863	Phase 4	Cystoscopic Fluid containing Neosporin G. U. Irrigant;Cystoscopic Fluid/Placebo
46	The Efficacy and Safety of Pivmecillinam in Treating Bacteriemic Urosepsis Caused by E.Coli	Completed	NCT03282006	Phase 4	pivmecillinam
47	Methenamine Hippurate Versus Trimethoprim in the Prevention of Recurrent UTIs	Completed	NCT03077711	Phase 4	Trimethoprim;Methenamine hippurate
48	The EDGE Consortium: A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Percutaneous Nephrolithotomy: Part 1	Completed	NCT02384200	Phase 4	nitrofurantoin monohydrate/macrocrystalline capsules;ampicillin;gentamicin;vancomycin;ceftriaxone
49	Efficacy and Safety of CRO-SBT Performed in Children With Acute Bacterial Infection	Completed	NCT04066621	Phase 4	Ceftriaxone Sodium and Sulbactam Sodium for Injection
50	A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region	Completed	NCT00986102	Phase 4	doripenem

Search NIH Clinical Center for Urinary Tract Infection

Cochrane evidence based reviews: urinary tract infections

Sources

Genetic Tests for Urinary Tract Infection

Sources

Anatomical Context for Urinary Tract Infection

Organs/tissues related to Urinary Tract Infection:

MalaCards : Spinal Cord, Kidney, Prostate, Neutrophil, Liver, Whole Blood, Skin

Sources

Publications for Urinary Tract Infection

Articles related to Urinary Tract Infection:

(show top 50) (show all 46002)

#	Title	Authors	PMID	Year
1	A post-trial follow-up study of pentosan polysulfate monotherapy on preventing recurrent urinary tract infection in women. ⁶² ⁴¹	Lee YJ...Tseng CS	36202908	2022
2	Femistina versus Canephron as a prevention of urinary tract infections after midurethral sling surgery - Non-inferiority study. ⁶² ⁴¹	Rechberger E...Rechberger T	36027670	2022
3	Effect of Educational intervention based on Health Belief Model on promoting preventive behaviours of urinary tract infections in mothers with children under 6-Years of age. ⁶² ⁴¹	Bazargani Z...Khani Jeihooni A	36199084	2022
4	Whole-genome sequencing of patients with rare diseases in a national health system. ⁵	Turro E...Ouwehand WH	32581362	2020
5	Rapid, direct, visualized and antibody-free bacterial detection with extra species identification and susceptibility evaluation capabilities. ⁶²	Zhao M...Wang X	36436466	2023
6	Neurocritical Care Aspects of Ischemic Stroke Management. ⁶²	Qaryouti D...Greene-Chandos D	36333037	2023
7	Immobilization of poly-L-lysine brush via surface initiated polymerization for the development of long-term antibacterial coating for silicone catheter. ⁶²	Liu J...Zhang W	36399903	2023
8	Retrospective Comparison of Cefdinir, Cephalexin, and Sulfamethoxazole-Trimethoprim in the Treatment of Outpatient Pediatric Urinary Tract Infections. ⁶²	Cardinale B...Mitchell M	35861216	2023
9	Fast identification and susceptibility determination of E. coli isolated directly from patients' urine using infrared-spectroscopy and machine learning. ⁶²	Abu-Aqil G...Salman A	36170776	2023
10	What are the risk factors for recurrent UTI with repeated ESBL-producing Enterobacteriaceae? A retrospective cohort study. ⁶²	Ahn ST...Oh MM	36195248	2023
11	Effects of aging on urinary tract epithelial homeostasis and immunity. ⁶²	Ligon MM...Mysorekar IU	36368522	2023
12	Interactions of microorganisms within a urinary catheter polymicrobial biofilm model. ⁶²	Allkja J...Azevedo NF	36123299	2023
13	Distribution and expression of virulence genes (hlyA, sat) and genotyping of Escherichia coli O25b/ST131 by multi-locus variable number tandem repeat analysis in Tehran, Iran. ⁶²	Asgharzadeh S...Mirkalantari S	36129793	2022
14	Spinal infection with intraspinal abscess or empyema and acute myelopathy: comparative analysis of diagnostics, therapy, complications and outcome in primary care. ⁶²	Kreutztrager M...Liebscher T	35657387	2022
15	Racial Differences in Urine Testing of Febrile Young Children Presenting to Pediatric Hospitals. ⁶²	Ramgopal S...Macy ML	34780020	2022
16	Effectiveness of herbal medicines to prevent and control symptoms of urinary tract infections and to reduce antibiotic use: A literature review. ⁶²	van Wietmarschen H...Baars E	36345487	2022
17	Distribution of virulence determinants among Escherichia coli ST131 and its H30/H30-Rx subclones in Turkey. ⁶²	Er DK...Uzuner H	36459132	2022
18	Intracellular uropathogenic Escherichia coli are undetectable in urinary bladders after oral mecillinam treatment: An experimental study in a pig model of cystitis. ⁶²	Stark K...Andersen TE	36244593	2022
19	Voided Volume for Assessment of Bladder Emptying After Female Pelvic Floor Surgery: A Randomized Controlled Trial. ⁶²	Popiel P...Harmanli O	36409638	2022
20	Minimally Invasive Lower Anterior Resections - Better than Open But Not All the Same. ⁶²	Lim JS...Jeyarajah DR	36469507	2022
21	Pharmacokinetic, Safety, and Tolerability Evaluations of Gepotidacin (GSK2140944) in Healthy Japanese Participants. ⁶²	Barth A...Swift B	36468634	2022
22	Heart Failure is Associated with Early Medical and Surgery-related Complications Following THA: A Propensity-Scored Analysis. ⁶²	Sequeira SB...Boucher HR	36470365	2022
23	Development and validation of models for detection of postoperative infections using structured electronic health records data and machine learning. ⁶²	Colborn KL...Meguid RA	36470694	2022
24	Drug synergy discovery of tavaborole and aminoglycosides against Escherichia coli using high throughput screening. ⁶²	Liu S...Wu Y	36454354	2022
25	Clean-catching urine from pigs: A method for collecting quality specimens for urinalysis and microbiological culturing in a laboratory environment. ⁶²	Stark K...Andersen TE	36457157	2022
26	Upper or lower tract approach for duplex anomalies? A bi-institutional comparative analysis of robot-assisted approaches. ⁶²	Sahadev R...Shukla AR	35079941	2022
27	Association between maternal infections during pregnancy and congenital defects in their offspring: a population-based case-control study in Bogota and Cali, Colombia 2001-2018. ⁶²	Rumbo J...Zarante I	34749588	2022
28	Clonal groups of extended-spectrum β-lactamase and biofilm producing uropathogenic Escherichia coli in Iran. ⁶²	Qasemi A...Katouli M	34904540	2022
29	Ceftazidime encephalopathy developed without the elevation of cerebrospinal fluid concentration of ceftazidime: A case report of two cases. ⁶²	Toda M...Ryuzaki M	36028210	2022
30	Evaluating the Need for Prolonged Telemetry Monitoring in Patients With Isolated Sternal Fractures. ⁶²	Al-Khouja F...Nahmias J	36030608	2022
31	Nurse-in-the-loop smart home detection of health events associated with diagnosed chronic conditions: A case-event series. ⁶²	Fritz R...Cook DJ	35642184	2022
32	The efficacy of the American College of Surgeons Surgical Risk Calculator in the prediction of postoperative complications in oncogeriatric patients after curative surgery for abdominal tumors. ⁶²	El Asmar A...Liberale G	35924711	2022
33	Implementation of a standardized voiding protocol after minimally invasive surgery: A quality improvement initiative. ⁶²	Kim SR...Bouchard-Fortier G	35490400	2022
34	Predicting mortality in moderate-severe TBI patients without early withdrawal of life-sustaining treatments including ICU complications: The MYSTIC-score. ⁶²	Chang HYM...Muehlschlegel S	36166912	2022
35	Preventing pediatric catheter-associated urinary tract infections utilizing urinary catheter Kamishibai cards (K-cards). ⁶²	Lehane R...Vaughan-Malloy AM	36463976	2022
36	Novel agents in development for multidrug-resistant Gram-negative infections: potential new options facing multiple challenges. ⁶²	Arya R...Shorr AF	36206150	2022
37	Infectious complications in adult patients with idiopathic minimal change nephrotic syndrome undergoing immunosuppressive therapy. ⁶²	Hsu CY...Lee PT	36209374	2022
38	Surgical treatment of proximal femoral fractures in centenarians: prevalence and outcomes based on a German multicenter study. ⁶²	Langenhan R...Reimers N	36469083	2022
39	Multinational Prospective Cohort Study of Mortality Risk Factors in 198 ICUs of 12 Latin American Countries over 24 Years: The Effects of Healthcare-Associated Infections. ⁶²	Rosenthal VD...Jin Z	36197596	2022
40	Transvaginal approach for rectovaginal fistula: experience from a single institution. ⁶²	Zeng Y...Wang X	36161396	2022
41	A Deception Study to Avoid Recall Bias Confirms Similar Scores for 3 Validated Questionnaires in the Office or Over the Phone in Women With or Without Urinary Incontinence. ⁶²	Reddy M...Zimmern P	36036901	2022
42	Impact of bacterial infections and spontaneous bacterial peritonitis prophylaxis on phage-bacterial dynamics in cirrhosis. ⁶²	Bajaj JS...Gillevet PM	35561076	2022
43	Feasibility of immediate removal of urinary catheter after laparoscopic gynecological surgery for benign diseases: A meta-analysis of randomized controlled trials. ⁶²	Fu CY...Wang LZ	35616374	2022
44	Zinner syndrome in children: clinical presentation, imaging findings, diagnosis, and outcome. ⁶²	Lin CC...Tsai JD	35332378	2022
45	Exposure to industrial hog and poultry operations and urinary tract infections in North Carolina, USA. ⁶²	Holcomb DA...Engel LS	36108846	2022
46	Simple determination of urine cefazolin concentration in pediatric patients with urinary tract infections using high-performance liquid chromatography. ⁶²	Abe K...Sasaki T	36049091	2022
47	Urinary tract infections in patients with multiple sclerosis and different methods of bladder evacuation. ⁶²	Varga G...Trinh T	36216764	2022
48	Bacterial filamentation during urinary tract infections. ⁶²	Abell-King C...Soderstrom B	36454736	2022
49	Reducing antibiotic use in uncomplicated urinary tract infections in adult women: a systematic review and individual participant data meta-analysis. ⁶²	Kau?ner Y...Gagyor I	35788049	2022
50	Usefulness of flow cytometry in the diagnosis of urinary tract infections caused by fastidious microorganisms: a case report of acute cystitis caused by Actinotignum schaalii. ⁶²	Ramos ISP...Tuesta-Del Arco JLD	35787349	2022

Sources

Genes for Urinary Tract Infection

Genes related to Urinary Tract Infection (1 elite genes):

(show all 49)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	EBF3	EBF Transcription Factor 3	Protein Coding	403.48	Pathogenic ⁵ DISEASES inferred ¹⁴	32581362
2	UMOD	Uromodulin	Protein Coding	23.68	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Functions (show sections)
3	HOGA1	4-Hydroxy-2-Oxoglutarate Aldolase 1	Protein Coding	12.75	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
4	CRP	C-Reactive Protein	Protein Coding	8.42	DISEASES inferred ¹⁴
5	SLC5A2	Solute Carrier Family 5 Member 2	Protein Coding	8.22	DISEASES inferred ¹⁴
6	SLC5A4	Solute Carrier Family 5 Member 4	Protein Coding	8.21	DISEASES inferred ¹⁴
7	UBAC1	UBA Domain Containing 1	Protein Coding	8.12	DISEASES inferred ¹⁴
8	ALB	Albumin	Protein Coding	8.08	DISEASES inferred ¹⁴
9	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	7.65	DISEASES inferred ¹⁴ ¹⁴
10	CD248	CD248 Molecule	Protein Coding	7.59	DISEASES inferred ¹⁴
11	IL6	Interleukin 6	Protein Coding	7.5	DISEASES inferred ¹⁴
12	INS	Insulin	Protein Coding	7.48	DISEASES inferred ¹⁴
13	KLK3	Kallikrein Related Peptidase 3	Protein Coding	7.44	DISEASES inferred ¹⁴
14	VIM	Vimentin	Protein Coding	7.38	DISEASES inferred ¹⁴
15	LCN2	Lipocalin 2	Protein Coding	7.29	DISEASES inferred ¹⁴
16	APEH	Acylaminoacyl-Peptide Hydrolase	Protein Coding	7.23	DISEASES inferred ¹⁴
17	UPK1A	Uroplakin 1A	Protein Coding	7.21	DISEASES inferred ¹⁴
18	TNF	Tumor Necrosis Factor	Protein Coding	7.15	DISEASES inferred ¹⁴
19	OXA1L	OXA1L Mitochondrial Inner Membrane Protein	Protein Coding	7.11	DISEASES inferred ¹⁴
20	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	7.1	DISEASES inferred ¹⁴
21	GPT	Glutamic--Pyruvic Transaminase	Protein Coding	7.08	DISEASES inferred ¹⁴
22	EPRS1	Glutamyl-Prolyl-TRNA Synthetase 1	Protein Coding	7.02	DISEASES inferred ¹⁴ ¹⁴
23	TLR4	Toll Like Receptor 4	Protein Coding	7.02	DISEASES inferred ¹⁴
24	ACE	Angiotensin I Converting Enzyme	Protein Coding	6.95	DISEASES inferred ¹⁴
25	NR3C2	Nuclear Receptor Subfamily 3 Group C Member 2	Protein Coding	6.94	DISEASES inferred ¹⁴
26	DPP4	Dipeptidyl Peptidase 4	Protein Coding	6.93	DISEASES inferred ¹⁴
27	IL1B	Interleukin 1 Beta	Protein Coding	6.92	DISEASES inferred ¹⁴
28	CD4	CD4 Molecule	Protein Coding	6.87	DISEASES inferred ¹⁴
29	PAPOLG	Poly(A) Polymerase Gamma	Protein Coding	6.86	DISEASES inferred ¹⁴
30	SERPINA3	Serpin Family A Member 3	Protein Coding	6.84	DISEASES inferred ¹⁴ ¹⁴
31	IL10	Interleukin 10	Protein Coding	6.81	DISEASES inferred ¹⁴
32	H2AC18	H2A Clustered Histone 18	Protein Coding	6.78	DISEASES inferred ¹⁴ ¹⁴
33	KCNIP1	Potassium Voltage-Gated Channel Interacting Protein 1	Protein Coding	6.77	DISEASES inferred ¹⁴
34	CFHR2	Complement Factor H Related 2	Protein Coding	6.75	DISEASES inferred ¹⁴ ¹⁴
35	REN	Renin	Protein Coding	6.67	DISEASES inferred ¹⁴
36	CST3	Cystatin C	Protein Coding	6.64	DISEASES inferred ¹⁴
37	F2	Coagulation Factor II, Thrombin	Protein Coding	6.62	DISEASES inferred ¹⁴
38	STX2	Syntaxin 2	Protein Coding	6.61	DISEASES inferred ¹⁴
39	UPK3A	Uroplakin 3A	Protein Coding	6.6	DISEASES inferred ¹⁴
40	SLC5A1	Solute Carrier Family 5 Member 1	Protein Coding	6.56	DISEASES inferred ¹⁴
41	HAVCR1	Hepatitis A Virus Cellular Receptor 1	Protein Coding	6.55	DISEASES inferred ¹⁴
42	ATP4A	ATPase H+/K+ Transporting Subunit Alpha	Protein Coding	6.52	DISEASES inferred ¹⁴
43	ATP12A	ATPase H+/K+ Transporting Non-Gastric Alpha2 Subunit	Protein Coding	6.52	DISEASES inferred ¹⁴
44	SPESP1	Sperm Equatorial Segment Protein 1	Protein Coding	6.52	DISEASES inferred ¹⁴
45	MDH2	Malate Dehydrogenase 2	Protein Coding	6.51	DISEASES inferred ¹⁴
46	CAMP	Cathelicidin Antimicrobial Peptide	Protein Coding	6.48	DISEASES inferred ¹⁴
47	GCG	Glucagon	Protein Coding	6.46	DISEASES inferred ¹⁴
48	F3	Coagulation Factor III, Tissue Factor	Protein Coding	6.41	DISEASES inferred ¹⁴
49	TLR2	Toll Like Receptor 2	Protein Coding	6.4	DISEASES inferred ¹⁴

Sources

Variations for Urinary Tract Infection

ClinVar genetic disease variations for Urinary Tract Infection:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	EBF3	NM_001375380.1(EBF3):c.280_283del (p.Glu94fs)	DEL	Pathogenic	375502	rs1057519521	GRCh37: 10:131761639-131761642 GRCh38: 10:129963375-129963378

Sources

Expression for Urinary Tract Infection

Search GEO for disease gene expression data for Urinary Tract Infection.

Sources

Pathways for Urinary Tract Infection

Pathways related to Urinary Tract Infection according to GeneCards Suite gene sharing:

(show all 21)

#	Super pathways	Score	Top Affiliating Genes
1	Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers ⁶⁵	11.9	ALB IL6 INS VIM
2	Spinal cord injury ⁷⁴	11.79	VIM TNF IL6 CXCL8
3	Allograft rejection ⁷⁴	11.74	VIM TNF CXCL8
4	Network map of SARS-CoV-2 signaling pathway ⁷⁴ Show member pathways Pathogenesis of SARS-CoV-2 mediated by nsp9-nsp10 complex ⁷⁴	11.65	IL6 CXCL8 CRP
5	Burn wound healing ⁷⁴	11.63	TNF IL6 CXCL8
6	CCL18 signaling pathway ⁷⁴	11.6	VIM IL6 CXCL8 CCR6
7	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.59	TNF IL6 CRP
8	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.59	VIM TNF LCN2 IL6 CXCL8
9	Photodynamic therapy-induced NF-kB survival signaling ⁷⁴ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.53	TNF IL6 CXCL8
10	Lung fibrosis ⁷⁴	11.52	TNF IL6 CXCL8
11	ATF-2 transcription factor network ⁶¹	11.47	INS IL6 CXCL8
12	Non-genomic actions of 1,25 dihydroxyvitamin D3 ⁷⁴	11.41	TNF IL6 CXCL8
13	Interleukin-10 signaling ⁶⁶	11.36	TNF IL6 CXCL8
14	miRNAs involvement in the immune response in sepsis ⁷⁴	11.35	TNF LCN2 IL6 CXCL8
15	Nonalcoholic fatty liver disease ⁷⁴	11.33	TNF INS IL6
16	Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway ⁷⁴	11.11	TNF IL6 CXCL8
17	Prostaglandin signaling ⁷⁴	11.03	TNF IL6 CXCL8
18	Immune infiltration in pancreatic cancer ⁷⁴	10.98	TNF IL6 CXCL8
19	COVID-19 adverse outcome pathway ⁷⁴	10.59	IL6 CXCL8
20	Overview of nanoparticle effects ⁷⁴	10.2	TNF IL6 CXCL8 CRP
21	Cells and molecules involved in local acute inflammatory response ⁷⁴ Show member pathways IL8-mediated signaling events ⁶¹	9.83	TNF IL6 CXCL8